Release
📈 Stocks
Lutris Pharma Reports 71.8% Success Rate in Phase 2 LUT014 Gel Trial
(21 days ago)
Lutris Pharma shares gain momentum after reporting that its LUT014 0.1% gel significantly outperformed placebo in Phase 2 trials, achieving a 71.8%…